Antiphospholipid antibodies (aPLs) are a heterogeneous group of antibodies directed against phospholipids or protein/phospholipid complexes. Currently, aPLs are assessed using either "solid-phase" assays that identify anticardiolipin antibodies and anti-β2-glycoprotein I antibodies or "liquid-phase" assay that identifies lupus anticoagulant. However, in the last few years, "new" antigenic targets and methodological approaches have been employed for refining laboratory diagnosis of antiphospholipid syndrome (APS). In this review the potential diagnostic value of antibodies to domains of β2-GPI, prothrombin/phosphatidylserine, vimentin/cardiolipin, protein S, protein C, annexin A2, annexin A5, and phospholipid antigens is discussed. Moreover, new technical approaches, including chemiluminescence, multiline dot assay, and thin layer chromatography (TLC) immunostaining, which utilize different supports for detection of aPL, have been developed. A special focus has been dedicated on "seronegative" APS, that is, those patients with a clinical profile suggestive of APS (thromboses, recurrent miscarriages, or foetal loss), who are persistently negative for the routinely used aPL. Recent findings suggest that, in sera from patients with SN-APS, antibodies may be detected using "new" antigenic targets (mainly vimentin/cardiolipin) or methodological approaches different from traditional techniques (TLC immunostaining). Thus, APS represents a mosaic, in which antibodies against different antigenic targets may be detected thanks to the continuously evolving new technologies.

Antiphospholipid antibodies (aPLs) are a heterogeneous group of antibodies directed against phospholipids or protein/phospholipid complexes. Currently, aPLs are assessed using either “solid-phase” assays that identify anticardiolipin antibodies and anti--glycoprotein I antibodies or “liquid-phase” assay that identifis lupus anticoagulant. However, in the last few years, “new” antigenic targets and methodological approaches have been employed for refiing laboratory diagnosis of antiphospholipid syndrome (APS). In this review the potential diagnostic value of antibodies to domains of-GPI, prothrombin/phosphatidylserine, vimentin/cardiolipin, protein S, protein C, annexin A2, annexin A5, and phospholipid antigens is discussed. Moreover, new technical approaches, including chemiluminescence, multiline dot assay, and thin layer chromatography (TLC) immunostaining, which utilize diffrent supports for detection of aPL, have been developed. A special focus has been dedicated on “seronegative” APS, that is, those patients with a clinical profie suggestive of APS (thromboses, recurrent miscarriages, or foetal loss), who are persistently negative for the routinely used aPL. Recent fidings suggest that, in sera from patients with SN-APS, antibodies may be detected using “new” antigenic targets (mainly vimentin/cardiolipin) or methodological approaches diffrent from traditional techniques (TLC immunostaining). Ths, APS represents a mosaic, in which antibodies against diffrent antigenic targets may be detected thanks to the continuously evolving new technologies.

"New" antigenic targets and methodological approaches for refining laboratory diagnosis of antiphospholipid syndrome / Misasi, Roberta; Capozzi, Antonella; Longo, Agostina; Recalchi, Serena; Lococo, E; Alessandri, Cristiano; Conti, Fabrizio; Valesini, Guido; Sorice, M.. - In: JOURNAL OF IMMUNOLOGY RESEARCH. - ISSN 2314-8861. - STAMPA. - 2015:858542(2015), pp. 1-13. [10.1155/2015/858542]

"New" antigenic targets and methodological approaches for refining laboratory diagnosis of antiphospholipid syndrome.

MISASI, Roberta;CAPOZZI, ANTONELLA;LONGO, Agostina;RECALCHI, SERENA;ALESSANDRI, cristiano;CONTI, FABRIZIO;VALESINI, Guido;
2015

Abstract

Antiphospholipid antibodies (aPLs) are a heterogeneous group of antibodies directed against phospholipids or protein/phospholipid complexes. Currently, aPLs are assessed using either "solid-phase" assays that identify anticardiolipin antibodies and anti-β2-glycoprotein I antibodies or "liquid-phase" assay that identifies lupus anticoagulant. However, in the last few years, "new" antigenic targets and methodological approaches have been employed for refining laboratory diagnosis of antiphospholipid syndrome (APS). In this review the potential diagnostic value of antibodies to domains of β2-GPI, prothrombin/phosphatidylserine, vimentin/cardiolipin, protein S, protein C, annexin A2, annexin A5, and phospholipid antigens is discussed. Moreover, new technical approaches, including chemiluminescence, multiline dot assay, and thin layer chromatography (TLC) immunostaining, which utilize different supports for detection of aPL, have been developed. A special focus has been dedicated on "seronegative" APS, that is, those patients with a clinical profile suggestive of APS (thromboses, recurrent miscarriages, or foetal loss), who are persistently negative for the routinely used aPL. Recent findings suggest that, in sera from patients with SN-APS, antibodies may be detected using "new" antigenic targets (mainly vimentin/cardiolipin) or methodological approaches different from traditional techniques (TLC immunostaining). Thus, APS represents a mosaic, in which antibodies against different antigenic targets may be detected thanks to the continuously evolving new technologies.
2015
Antiphospholipid antibodies (aPLs) are a heterogeneous group of antibodies directed against phospholipids or protein/phospholipid complexes. Currently, aPLs are assessed using either “solid-phase” assays that identify anticardiolipin antibodies and anti--glycoprotein I antibodies or “liquid-phase” assay that identifis lupus anticoagulant. However, in the last few years, “new” antigenic targets and methodological approaches have been employed for refiing laboratory diagnosis of antiphospholipid syndrome (APS). In this review the potential diagnostic value of antibodies to domains of-GPI, prothrombin/phosphatidylserine, vimentin/cardiolipin, protein S, protein C, annexin A2, annexin A5, and phospholipid antigens is discussed. Moreover, new technical approaches, including chemiluminescence, multiline dot assay, and thin layer chromatography (TLC) immunostaining, which utilize diffrent supports for detection of aPL, have been developed. A special focus has been dedicated on “seronegative” APS, that is, those patients with a clinical profie suggestive of APS (thromboses, recurrent miscarriages, or foetal loss), who are persistently negative for the routinely used aPL. Recent fidings suggest that, in sera from patients with SN-APS, antibodies may be detected using “new” antigenic targets (mainly vimentin/cardiolipin) or methodological approaches diffrent from traditional techniques (TLC immunostaining). Ths, APS represents a mosaic, in which antibodies against diffrent antigenic targets may be detected thanks to the continuously evolving new technologies.
anti-phospholipid antibodies; anti-cardiolipin antibodies; systemic lupus erythematosus
01 Pubblicazione su rivista::01a Articolo in rivista
"New" antigenic targets and methodological approaches for refining laboratory diagnosis of antiphospholipid syndrome / Misasi, Roberta; Capozzi, Antonella; Longo, Agostina; Recalchi, Serena; Lococo, E; Alessandri, Cristiano; Conti, Fabrizio; Valesini, Guido; Sorice, M.. - In: JOURNAL OF IMMUNOLOGY RESEARCH. - ISSN 2314-8861. - STAMPA. - 2015:858542(2015), pp. 1-13. [10.1155/2015/858542]
File allegati a questo prodotto
File Dimensione Formato  
Misasi_Antiphospholipid Syndrome_2015.pdf

solo gestori archivio

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 2.09 MB
Formato Adobe PDF
2.09 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/780876
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 43
  • ???jsp.display-item.citation.isi??? 32
social impact